劉強東涉性侵案雙方達成和解協議
據《界面新聞》報道,針對京東集團(09618.HK)(JD.US)創辦人兼主席劉強東被指涉嫌於2018年在美國性侵一名中國留學生而被女事主提出民事訴訟一事,據內地媒體引述劉強東代理律師指出,雙方在開庭前兩日達成和解協議,惟未有透露金額。
報道引述一份雙方律師團隊的聯合聲明稱,劉強東和劉婧堯於2018年在美國明尼蘇達的一次偶然事件所造成的誤會,佔用了大量的社會資源,也給彼此的家庭造成了深重的困擾。爲避免進一步的訴訟傷害,雙方決定消除誤會,達成和解,爲這次事件畫上句號。除該聲明外,劉婧堯及其代表和律師不再發表任何評論,雙方也不會出具其它的聯合聲明。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.